Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycofertilic Prime is an oral high-potency fertility-support nutraceutical developed by Cambridge Diagnostic Imaging and Lycotec for women preparing for egg retrieval and in vitro fertilization procedures. The product is positioned as an intensified formulation of Lycofertilic and contains a patented combination of docosahexaenoic acid derived from algae together with lutein and zeaxanthin, with the stated aim of improving bioavailability and providing antioxidant and membrane-supportive nutrition for oocytes and ovarian reserve. It is marketed as a vegan, GMO-free dietary supplement for pre-IVF use rather than as a pharmaceutical medicine, and its intended use is supportive optimization of egg quality rather than direct receptor-targeted pharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lycofertilic Prime.